Obesity Clinical Trial
Official title:
Immunometabolic Effects of Time Restricted Eating in Non-alcoholic Fatty Liver Disease
This study will assess the impact of 8-hour time restricted eating (8 hours of eating, 16 hours fasting) combined with a Mediterranean diet on metabolism and inflammation in adults with non-alcoholic fatty liver disease (NAFLD).
Status | Recruiting |
Enrollment | 60 |
Est. completion date | July 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Males and females - Age 18-65 years, from all ethnic groups, capable of providing informed consent to participate - Obesity (body mass index >30kg/m^2) and of stable body weight (±3% for =3 months) - Fasting blood glucose <7.0 mmol/L and HbA1c <6.5%. - Liver fat >10% (CAP score >238 dB/m) and no fibrosis (liver stiffness score 2-7 kPa) as assessed by liver elastography (FibroScan) Exclusion Criteria: - Impaired renal function - Abnormal hematocrit - History of cardiovascular events - Uncontrolled hypertension - Type 2 diabetes - Medications or supplements known to affect glucose or lipid metabolism - Active inflammatory, autoimmune, infectious, gastrointestinal, or malignant disease - Uncontrolled neurological or psychiatric disease - Iron deficiency anemia, (hemoglobin < 12g/dl men, < 11g/dl women) - Fatty acid supplements and consumers of high doses of anti- antioxidant vitamins (A, C, E, b-carotene) |
Country | Name | City | State |
---|---|---|---|
Ireland | University College Dublin | Dublin | Leinster |
Lead Sponsor | Collaborator |
---|---|
University College Dublin | St. James's Hospital, Ireland |
Ireland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in plasma inflammatory response to a high-fat meal: C-reactive protein (CRP) | Postprandial changes in CRP (mg/L) will be measured in response to a high-fat meal | To be assessed at baseline and post 8-week intervention | |
Primary | Change in plasma inflammatory response to a high-fat meal: Interleukin-6 (IL-6) | Postprandial changes in IL-6 (pg/mL) will be measured in response to a high-fat meal | To be assessed at baseline and post 8-week intervention | |
Primary | Change in plasma inflammatory response to a high-fat meal: Interleukin-1-beta (IL-1ß) | Postprandial changes in IL-1ß (pg/mL) will be measured in response to a high-fat meal | To be assessed at baseline and post 8-week intervention | |
Primary | Change in plasma inflammatory response to a high-fat meal: Tumor necrosis factor alpha (TNF-a) | Postprandial changes in (TNF-a) (pg/mL) will be measured in response to a high-fat meal | To be assessed at baseline and post 8-week intervention | |
Secondary | Change in metabolic response to a high-fat meal: Glucose | Plasma glucose (mg/dL) response to a high-fat meal will be assessed | To be assessed at baseline and post 8-week intervention | |
Secondary | Change in metabolic response to a high-fat meal: Insulin | Plasma insulin (µU/mL) response to a high-fat meal will be assessed | To be assessed at baseline and post 8-week intervention | |
Secondary | Change in metabolic response to a high-fat meal: Glucagon | Plasma glucagon (pg/mL) response to a high-fat meal will be assessed | To be assessed at baseline and post 8-week intervention | |
Secondary | Change in metabolic response to a high-fat meal: Triglycerides | Plasma triglycerides (mg/dL) response to a high-fat meal will be assessed | To be assessed at baseline and post 8-week intervention | |
Secondary | Change in metabolic response to a high-fat meal: Non-esterified fatty acids (NEFA) | Plasma NEFA (mmol/L) response to a high-fat meal will be assessed | To be assessed at baseline and post 8-week intervention | |
Secondary | Innate immune function | 8-week change in innate immune function will be assessed ex-vivo using whole blood simulation assay. | To be assessed at baseline and post 8-week intervention | |
Secondary | Innate immune training | 8-week change in innate immune function will be assessed in isolated monocytes stimulated with beta glucan and restimulated with lipopolysaccharide. | To be assessed at baseline and post 8-week intervention | |
Secondary | Insulin resistance | 8-week change in insulin resistance using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). | To be assessed at baseline and post 8-week intervention | |
Secondary | Adipose tissue insulin resistance | 8-week change in adipose tissue insulin resistance using the adipose tissue insulin resistance index (Adipo-IR). | To be assessed at baseline and post 8-week intervention | |
Secondary | Change in intrahepatic triglyceride content | Liver elastography (FibroScan) will be used to determine change in liver fat after the 8-week intervention. | To be assessed at baseline and post 8-week intervention | |
Secondary | Change in liver stiffness measurement | Liver elastography (FibroScan) will be used to determine change in liver stiffness after the 8-week intervention. | To be assessed at baseline and post 8-week intervention | |
Secondary | HDL Proteome | 8-week change in the composition of the HDL proteome. | To be assessed at baseline and post 8-week intervention | |
Secondary | Body weight | 8-week change in body weight in kilograms | To be assessed at baseline and post 8-week intervention | |
Secondary | Body mass index (BMI) | 8-week change in BMI | To be assessed at baseline and post 8-week intervention | |
Secondary | Body fat percentage | 8 week change in body fat percentage using bioelectrical impedance analysis | To be assessed at baseline and post 8-week intervention | |
Secondary | Waist and hip circumferences | 8-week change in waist and hip circumference measured in centimeters using a body tape measure | To be assessed at baseline and post 8-week intervention | |
Secondary | Gut microbiome composition and function | 8-week functional changes in gut microbiome will be assessed by integrating 16S sequencing of fecal samples with fecal water metabolomics. | To be assessed at baseline and post 8-week intervention | |
Secondary | Dietary intake | 8-week change in dietary intake using a 3-day semi-weighed food diary. | To be assessed at baseline and post 8-week intervention | |
Secondary | Physical activity level (PAL) | 8-week change in PAL using the International Physical Activity Questionnaire - Short form (IPAQ-SF). This form has 7 questions about time spent doing physical activity(leisure time, work, domestic tasks, and travel) in the last 7 days. Activities are grouped according to vigorous or moderate intensity, and walking. Each intensity is assigned a metabolic equivalent (MET). The time spent at each intensity is used to estimate weekly physical activity using the associated METs. Minimum and maximum values are 0 and 154,224 METs. Classification as 'sufficiently active' requires =600 METs/week which may be achieved through a combination of intensities. Classification as 'highly active' requires: a) vigorous-intensity activity on =3 days achieving a minimum of =1500 METs/week OR b) =7 days of any combination of walking, moderate-intensity or vigorous-intensity activities achieving = 3000 METs/week. A physical activity level below these categories is undesirable. | To be assessed at baseline and post 8-week intervention | |
Secondary | Mediterranean diet adherence | 8-week change in Mediterranean diet adherence score using the PREDIMED 14-item Mediterranean Diet Assessment Tool. This questionnaire is used to assess adherence to the traditional Mediterranean Diet. Two of the 14 questions relate to the use of olive oil, a key component of the Mediterranean Diet, and 12 questions relate to the consumption of foods which characterize the Mediterranean Diet. Each item has a criteria which must be met to achieve 1 point e.g., at least 3 pieces of fruit daily. The minimum score is 0 and the maximum is 14, where a score of = 5 indicates low adherence, 6-9 moderate adherence, and > 9 high adherence. | To be assessed at baseline and post 8-week intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |